Hatem Soliman News Today

Tremendous progress has been made in the treatment landscape for HER2-positive breast cancer that has significantly altered and improved the outlook for this patient population.

Current high survival rates demonstrate why a diagnosis now isn’t what it used to be.

Onlytic virus, in conjugation with systemic chemotherapy, may boost responses in high risk, early stage triple-negative breast cancer.

Only a few courses are available globally that cover this integrated topic for medical practitioners

About one in eight women will be diagnosed with breast cancer in their lifetime. Experts say African American women are more likely to die of breast cancer than white women.

Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium - 88.6% of Evaluable 1L TNBC... | December 10, 2021

 MARIO-3 Phase 2 study evaluating eganelisib added to standard of care Tecentriq® and Abraxane® regimen in frontline triple negative breast cancer (TNBC)Investor Event with KOL Scheduled for Friday, December 10th @ 9:30am ETCAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-...

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this years American Society of Clinical Oncology (ASCO) Annual Meeting, the worlds largest clinical cancer research meeting. Moffitt investigators will lead 25 abstract presentat...

 E-Mail TAMPA, Fla. - Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this years American Society of Clinical Oncology (ASCO) Annual Meeting, the worlds largest clinical cancer research meeting. Moffitt investigators will lead 25 abstract presentations, five education sessions, two cancer-based panels and two cli...